Table 1 Patient characteristics

Age [years], median, mean, range

70, 69, 57–80

Time between ADT initiation and second [⁶⁸Ga]Ga-PSMA-PET [days], median, mean, range

155, 158, 61–289

PSA value at [⁶⁸Ga]Ga-PSMA-PET (T1), median, mean, range [ng/ml]

29.1, 39.0, 2.5–107.0

PSA value at [⁶⁸Ga]Ga-PSMA-PET (T2), median, mean, range [ng/ml]

0.71, 1.24, 0.05–4.91

Lesions T1 versus T2

Prostate tumor [n: patients; n: lesions]

21 versus 17; 24 versus 18

Lymph node metastases [n: patients; n: lesions]

16 versus 10; 56 versus 20

Bone metastases [n: patients; n: lesions]

14 versus 10; 27 versus 12^a

Sum [n: lesions]

107 versus 50^a

∑ PSMA derived tumor volume (PSMA-TV) of all lesions at T1, sum [ml]

505.69

∑ PSMA derived tumor volume (PSMA-TV) of all lesions T2, sum [ml], (% of T1)

121.51 (24.0%)

∑ Total lesion PSMA (TL-PSMA) of all lesions at T1, sum [ml]

9016.32

∑ Total lesion PSMA (TL-PSMA) of all lesions at T2, sum [ml], (% of T1)

1256.91 (13.9%)